Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Votes Abstained Broker Non-Vote 24,238,701 222,804 19,363 —
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2024-05-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 3 Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,786,239 573,411 25,950 4,095,268
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Fulgent Genetics, Inc. shareholders approved Election of directors at the 2024-05-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 20,071,185 314,415 4,095,268 Michael Nohaile, Ph.D. 17,462,830 2,922,770 4,095,268 Regina Groves 17,487,701 2,897,899 4,095,268 Linda Marsh 15,854,682 4,530,918 4,095,268
View on SEC.gov